The economics of febrile neutropenia: implications for the use of colony-stimulating factors

This publication has 23 references indexed in Scilit:

• Granulocyte Colony-Stimulating Factor in Severe Chemotherapy-Induced Afebrile Neutropenia
  New England Journal of Medicine, 1997
• Cancer statistics, 1997
  CA: A Cancer Journal for Clinicians, 1997
• Economic analysis of the use of recombinant human granulocyte colony stimulating factor in autologous bone marrow transplantation
  European Journal Of Cancer, 1996
• Improving Treatment of Chemotherapy-Induced Neutropenic Fever by Administration of Colony-Stimulating Factors
  JNCI Journal of the National Cancer Institute, 1995
• The costs of peripheral blood progenitor cell reinfusion mobilised by granulocyte colony-stimulating factor following high dose melphalan as compared with conventional therapy in multiple myeloma
  European Journal Of Cancer, 1994
• Decision Analysis of Hematopoietic Growth Factor Use in Patients Receiving Cancer Chemotherapy
  JNCI Journal of the National Cancer Institute, 1993
• Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy
  European Journal Of Cancer, 1993
• Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer
  New England Journal of Medicine, 1991
• Effect of Granulocyte Colony-Stimulating Factor on Neutropenia and Associated Morbidity Due to Chemotherapy for Transitional-Cell Carcinoma of the Urothelium
  New England Journal of Medicine, 1988
• A Randomized Trial Comparing Ceftazidime Alone with Combination Antibiotic Therapy in Cancer Patients with Fever and Neutropenia
  New England Journal of Medicine, 1986